Investment Thesis
Arvinas is a pre-commercial biotech company with minimal revenue ($15.6M) relative to massive operating losses ($63.8M), burning $70.5M annually in free cash flow. While the balance sheet is strong with $87.3M cash and minimal debt, the company has less than 1.2 years of cash runway at current burn rates with no clear path to profitability visible in current financials.
Strengths
- Strong balance sheet with $87.3M cash and essentially debt-free capital structure
- Excellent liquidity position (5.44x current ratio) provides operational flexibility
- Improving loss metrics year-over-year (EPS improved 58.8% YoY shows cost management progress)
- Substantial stockholder equity base ($386.8M) provides downside protection
Risks
- Severe cash burn of $70.5M annually against only $15.6M revenue indicates unsustainable operations
- Limited cash runway of approximately 1.2 years at current burn rate without additional funding
- Extreme negative profitability metrics (operating margin -409%, net margin -369.2%) indicate core business dysfunction
- Operating losses 4x larger than annual revenue with no demonstrated progress toward breakeven
- Typical biotech execution risk: success depends entirely on clinical trial outcomes and regulatory approvals not reflected in current financials
Key Metrics to Watch
- Cash burn rate and operating cash flow - must show meaningful deceleration or additional funding
- Revenue growth and new product contributions - current $15.6M base is insufficient to sustain operations
- Operating expense trends - management must demonstrate ability to right-size cost structure
- Clinical development milestones and regulatory progress from pipeline candidates
- Whether company announces major funding round, partnership, or acquisition activity before cash depletes
Financial Metrics
Revenue
15.6M
Net Income
-57.6M
EPS (Diluted)
$-0.90
Free Cash Flow
-70.5M
Total Assets
647.5M
Cash
87.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-409.0%
Net Margin
-369.2%
ROE
-14.9%
ROA
-8.9%
FCF Margin
-451.9%
Balance Sheet & Liquidity
Current Ratio
5.44x
Quick Ratio
5.44x
Debt/Equity
0.00x
Debt/Assets
40.3%
Interest Coverage
N/A
Long-term Debt
500.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T07:49:37.338600 |
Data as of: 2026-03-31 |
Powered by Claude AI